We are delighted that, despite the Covid-19 crisis and lab lockdown, we have been able to raise over £1.3m mezzanine B2 funding for the continuation of our pioneering research on Alzheimer’s disease. We are very grateful to our existing investors for their continued support, as well as welcoming new subscribers. In addition, the Future Fund scheme from the UK government has proved a huge benefit in increasing incoming funds still further. In the immediate future, we shall now plan for a significant Series C round for taking to the investment community towards the end of Q1 2021.
LATEST NEWS
- Baroness Greenfield to attend NeuRA (Neuroscience Research Australia) Sydney in May 2024!
- Baroness Greenfield to speak at the Early Career Dementia Researchers Retreat in June 2024!
- Transforming Alzheimer’s Disease Detection – Collaboration with Aptamer Group
- THENA Capital podcast with Baroness Susan Greenfield
- Neuro-Bio and Aptamer enter the second phase of Alzheimer’s test development